New weight-loss drug is ‘better than Wegovy’ — and comes in a pill
The Timesarrow_outwardNew weight-loss pill ‘better than jabs’
The Telegrapharrow_outwardNew Novo Nordisk drug could beat market leaders for weight loss, early results show
Financial Timesarrow_outwardWeight loss pill shows promise in new trial - Radio News Hub
Radio News Hubarrow_outwardWeight loss pill set to rival injections after promising studies - MSN
MSNarrow_outwardNovo Nordisk's experimental drug results in up to 24% weight loss - Reuters
Reutersarrow_outwardNovo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 - Yahoo Finance
Yahoo Financearrow_outwardOzempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL - Daily Mail
Daily Mailarrow_outwardWeight loss pill set to rival injections after promising studies - The Independent
The Independentarrow_outwardNovo’s Latest Obesity Drug Shows 24% Weight Loss in Small Trial - Bloomberg.com
Bloomberg.comarrow_outwardADA25: Injected version of Novo's amycretin surpasses 24% weight loss - FirstWord Pharma
FirstWord Pharmaarrow_outwardNovo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development - Indian Pharma Post
Indian Pharma Postarrow_outwardDiscover An Ozempic alternative shows promising weight loss results — and Novo Nordisk stock surges 12% - Quartz
Quartzarrow_outwardNovo's GLP-1/Amylin Dual Agonist Amycretin to Enter Late-Stage Trials for Obesity - Patient Care Online
Patient Care Onlinearrow_outwardNovo, searching for a spark, plans late-stage trials for amylin drug - BioPharma Dive
BioPharma Divearrow_outwardNovo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company - Benzinga
Benzingaarrow_outwardNovo Nordisk plots phase 3 trials for next-gen obesity asset amycretin - Fierce Biotech
Fierce Biotecharrow_outwardNovo Nordisk to advance SC and oral amycretin development - The Pharma Letter
The Pharma Letterarrow_outwardNovo Nordisk Advances Amycretin to Phase 3 for Weight Management - TipRanks
TipRanksarrow_outwardNovo Nordisk ramps up obesity fight, advances amycretin to Phase III - Clinical Trials Arena
Clinical Trials Arenaarrow_outwardNovo Nordisk takes amycretin for overweight into phase 3 - MarketScreener
MarketScreenerarrow_outwardNovo Nordisk To Start Phase 3 Trial Of Amycretin For Weight Loss In Early 2026 - Nasdaq
Nasdaqarrow_outwardNovo Nordisk plans to start late-stage trials of obesity drug amycretin next year - Global Banking | Finance | Review
Global Banking | Finance | Reviewarrow_outwardNovo Nordisk plans Phase 3 trials of oral, injectable amycretin for early 2026 - Endpoints News
Endpoints Newsarrow_outwardNovo Nordisk (NVO) Advances Obesity Drug Amycretin to Phase 3 Trials - GuruFocus
GuruFocusarrow_outwardNovo Nordisk plans late-stage trials for weight-loss drug amycretin - Investing.com Nigeria
Investing.com Nigeriaarrow_outwardNovo Nordisk plans late-stage trials for weight-loss drug amycretin - Investing.com India
Investing.com Indiaarrow_outwardNovo Nordisk plans late-stage trials for weight-loss drug amycretin - Investing.com Canada
Investing.com Canadaarrow_outwardNovo Nordisk plans late-stage trials for weight-loss drug amycretin - Investing.com
Investing.comarrow_outwardNovo Nordisk plans late-stage trials for weight-loss drug amycretin - Investing.com UK
Investing.com UKarrow_outwardNovo Nordisk plans to start late-stage trials of obesity drug amycretin next year - PharmaLive
PharmaLivearrow_outwardNovo Nordisk plans to start late-stage trials for experimental obesity drug amycretin - WSAU
WSAUarrow_outwardNovo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development - The Manila Times
The Manila Timesarrow_outwardNovo Nordisk Announces Top-Line Results for Amycretin as Potential Obesity, Overweight Treatment - Pharmacy Times
Pharmacy Timesarrow_outwardSubcutaneous Amycretin Shows Weight Loss of 9.7% for 20 Weeks - Drug Topics
Drug Topicsarrow_outwardForget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands - The Motley Fool
The Motley Foolarrow_outwardAmycretin Shows Promising 22% Weight Loss in Trials—It May Rival Ozempic - firstforwomen.com
Firstforwomen.comarrow_outwardAmycretin Shows Promising 22% Weight Loss in Trials—It May Rival Ozempic - Yahoo
Yahooarrow_outwardNovo Nordisk: New GLP-1 Drug Shows Leading Weight Loss in Small Trial - Morningstar
Morningstararrow_outwardNovo Nordisk may take new weight-loss drug directly into phase 3 - medwatch.com
Medwatch.comarrow_outwardNovo Nordisk reports positive next-generation obesity drug trial - Euronews.com
Euronews.comarrow_outwardNovo Nordisk Obesity Drug Shows 22% Weight Loss, But Lack of Safety Detail Is a Sticking Point - MedCity News
MedCity Newsarrow_outwardNovo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss - BioSpace
BioSpacearrow_outwardSubcutaneous Amycretin Yields Promising Weight Loss in Phase 1b/2a Trial - HCPLive
HCPLivearrow_outwardNovo Nordisk leaps on new obesity drug data - Pharmaphorum
Pharmaphorumarrow_outwardNovel obesity drug induces up to 22% weight loss with no safety concerns - Healio
Healioarrow_outwardNovo Nordisk’s amycretin cuts weight by 22% in early obesity trial - Medical Marketing and Media
Medical Marketing and Mediaarrow_outwardWhy Novo Jumped — And Took Out Lilly And Viking Stocks - Investor's Business Daily
Investor's Business Dailyarrow_outwardNovo Nordisk Shares Surge on New Obesity Drug Results - WSJ
WSJarrow_outwardNovo Nordisk’s next-generation obesity treatment shows promise in early study - STAT
STATarrow_outwardNovo Nordisk Stock Soars on New Weight-Loss Drug Data. Eli Lilly Stock Falls. - Barron's
Barron'sarrow_outwardNovo Nordisk shares pop on early-stage weight loss drug trial results - CNBC
CNBCarrow_outwardNovo Nordisk’s New Weight Loss Drug Sends Stock Soaring - Wall Street Pit
Wall Street Pitarrow_outwardNovo Nordisk's Experimental Oral Drug Reports 'Remarkable' Weight Loss, Early Data Shows - Verywell Health
Verywell Healtharrow_outwardWegovy makers say new amycretin weight-loss pill even more effective - Pulse Today
Pulse Todayarrow_outwardNew Oral Weight Loss Drug Cuts Body Weight by 13% in Just 12 Weeks - SciTechDaily
SciTechDailyarrow_outwardEarly trial shows success for daily weight loss pill: 3 things to know - ABC News - Breaking News, Latest News and Videos
ABC News - Breaking News, Latest News and Videosarrow_outwardNovo’s New Weight Loss Drug Is More Effective Than Wegovy In Early Trial - Forbes
Forbesarrow_outwardAmycretin data highlight supply challenges for oral peptides in obesity - biocentury.com
Biocentury.comarrow_outwardNew Ozempic-like pill reduces weight by 13%, study finds - BBC Science Focus Magazine
BBC Science Focus Magazinearrow_outwardOral obesity therapies: Holding the key to the future - IQVIA
IQVIAarrow_outwardBeyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better? - Labiotech.eu
Labiotech.euarrow_outward
Amycretin close
- 2025-06-21 15:10 event
- 62 sourceslanguage
- 100+ ads_click
- 2 days ago schedule